This CME program will highlight recent advances in the treatment and management of patients with myasthenia gravis (MG). The expert faculty, Dr. James F. Howard Jr., will first outline the pathophysiology and disease course of MG, referencing the impact of treatment and disease burden on patients. Following, current clinical trial data, including that of complement inhibitor therapies in generalized myasthenia gravis, will be analyzed and clinical relevance debated. The program will conclude with final thoughts and a summary of unmet needs in the MG treatment landscape. Upon completion of this CME activity, learners will be equipped with pertinent information for improving outcomes and quality of life for patients with myasthenia gravis.
Neurologists, neuromuscular specialists, and other healthcare professionals involved in the treatment and management of patients with generalized myasthenia gravis
I. Update on the Science of Myasthenia Gravis and the Rationale for Non-Steroidal Immune-Mediated Therapy; Which Patients Should Be Referred for Subspecialty Care?
II. Clinical Trial Review and Mechanism of Action for FcRn Blockers for Patients with Generalized Myasthenia Gravis
III. Clinical Applications of FcRn Blockers in gMG: A Case Presentation Series
- Understand the pathophysiology and disease course of myasthenia gravis, the rationale for targeted, non-steroidal immune-mediated therapy, and appropriate referral of patients for targeted therapy
- Explain the mechanism of action of FcRn blockers and related clinical trial data for the treatment of patients with generalized myasthenia gravis
- Review treatment plans to apply FcRn blocker therapeutics to improve outcomes for patients with generalized myasthenia gravis
James F. Howard Jr., MD
Professor of Neurology & Medicine
The University of North Carolina School of Medicine
Chapel Hill, North Carolina
Disclosures of Relevant Financial Relationships
It is the policy of AcademicCME that all faculty, instructors, and planners disclose relevant financial relationships with ineligible companies. Any relevant financial relationships related to this activity have been mitigated.
Planners and faculty have no relevant financial relationships with ineligible companies for this activity, with the exception of the following:
|Faculty||Relationship Identified With:|
|James F. Howard Jr., MD||Consultant/Advisor: Alexion Pharmaceuticals, Inc.; argenX; Horizon Therapeutics plc; Immunovant, Inc.; Ra Pharmaceuticals; Regeneron Pharmaceuticals Inc.; Sanofi-Aventis U.S. LLC; Toleranzia AB; UCB S.A.; Viela Bio, Inc.
Research/Grant Support: Alexion Pharmaceuticals, Inc.; argenX; Cartesian Therapeutics; The Centers for Disease Control and Prevention; Millennium Pharmaceuticals; National Institutes of Health; Patient-Centered Outcomes Research Institute; Ra Pharmaceuticals; UCB S.A.
Stock: Johnson & Johnson Services, Inc.; Pfizer Inc.; GlaxoSmithKline; General Electric
Planners and Peer Reviewers
Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Chelsey Benedek and Nicole McMenamin state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statements
AcademicCME designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditsTM.
This activity has been supported by an educational grant from argenX.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and argenX do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
In order to claim credit, participants must complete the following:
- Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
2. Complete the Pre-Activity Questions
3. Read or Review the activity content.
4. Complete the Post-Activity Test Questions and Evaluation.
5. Learners who receive a grade of 60% or better on the Post-Activity Test Questions andcomplete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
- CPE credit will be posted to the learner’s CPE Monitor profile within 60 days of completion.
- CME and CNE credit will be issued appropriate certificate of completion.
- Others may request a “certificate of completion”.
- Learners should claim only the credit commensurate with the extent of their participation in the activity.
CE Inquiries/Special Needs
For all CE inquiries or special needs, please contact [email protected].